Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

4th Clinical Microbiology and Microbial Genomics Conference

Philadelphia, USA

Mahin Khatami

Mahin Khatami

National Cancer Institute, USA

Title: Accidental Discoveries on Systematic Studies of Tumorigenesis and Angiogenesis: Perspectives for Prevention and Therapy of Antigen (Virus)-Causing Cancers.

Biography

Biography: Mahin Khatami

Abstract

Factors responsible for extremely slow progress in cancer research and failed therapies include absence of systematic studies on multistep tumorigenesis and ongoing controversies and misunderstanding on the roles that inflammation play in carcinogenesis and angiogenesis. In 1980’s our experimental models of acute and chronic ocular inflammatory diseases resulted in tumorigenesis and angiogenesis. Recent analyses of original data became ‘accidental’ discoveries on systematic identification of time-course kinetics of interaction and synergies between host immune cells (e.g., mast, goblet and B cells) and recruiting cells (e.g., eosinophils, macrophages) during acute, intermediate and chronic phases of inflammatory responses and induction of hyperplasia of conjunctival-associated lymphoid tissues. Results are the first systematic studies on sequential alterations of immunity toward tissue growth. Acute inflammation was defined as balance between two biologically opposing arms (Yin-Yang) of immune and non-immune (e.g., vasculature, neurodegenerative and metabolic) responses. Chronic inflammation or loss of balance in Yin and Yang of immunity was hypothesized as common link in genesis of all age-associated chronic diseases or cancer. Future efforts to promote immunity should include systematic understanding of host-pathogen interactions in susceptible tissues. Outcomes are expected to hold real promises in understanding how cancer cells become threat to body and how translate cancer biology into cost-effective drug designs and clinical trials.